Next-Generation Hemostatic Compositions and Systems

Publication ID: 24-11857564_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Hemostatic Compositions and Systems,” Published Technical Disclosure No. 24-11857564_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857564_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,564.

Summary of the Inventive Concept

This inventive concept envisions a paradigm shift in hemostatic compositions and systems, integrating advanced materials, personalized medicine, and wearable technologies to revolutionize bleeding control and management.

Background and Problem Solved

The original patent disclosed hemostatic compositions comprising an anion exchanger and a calcium salt. However, these compositions have limitations in terms of efficacy, specificity, and user convenience. The new inventive concept addresses these limitations by introducing nanofibrous matrices, personalized formulations, wearable devices, and targeted delivery mechanisms.

Detailed Description of the Inventive Concept

The next-generation hemostatic compositions and systems comprise nanofibrous matrices incorporating an anion exchanger and a calcium salt, which can self-assemble into hierarchical structures. Additionally, the concept includes personalized formulations tailored to individual bleeding profiles, wearable devices with sensors for detecting bleeding, and targeted delivery mechanisms using conjugated targeting moieties. These advancements enable enhanced hemostatic efficacy, improved user experience, and expanded applications in various medical fields.

Novelty and Inventive Step

The new claims introduce a significant inventive step by integrating advanced materials, personalized medicine, and wearable technologies, which are not obvious from the original patent. The use of nanofibrous matrices, conjugated targeting moieties, and wearable devices with sensors for detecting bleeding are novel and non-obvious features that distinguish the new inventive concept from the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different types of nanofibrous matrices, various targeting moieties, or alternative wearable device designs. Additionally, the concept could be adapted for use in veterinary medicine or in combination with other therapeutic agents.

Potential Commercial Applications and Market

The next-generation hemostatic compositions and systems have significant commercial potential in the medical device and pharmaceutical industries, with potential applications in trauma care, surgical settings, and emergency response situations. The market for these innovative products is expected to be substantial, driven by the growing need for effective bleeding control and management solutions.

Field of Art

Biomedical engineering and hemostatic composition design, focusing on materials science, polymer chemistry, and medical device technologies with expertise in anion exchange materials and blood interaction mechanisms

Person of Ordinary Skill (PHOSITA) Profile

A researcher or engineer with advanced degrees in biomedical engineering or materials science, possessing knowledge of polymer chemistry, medical device design, and hemostatic material development, with understanding of ion exchange principles and blood interaction mechanisms

Obviousness Rationale

A person having ordinary skill in the art would recognize that the published technical disclosure represents predictable variations and extensions of the source patent's core hemostatic composition technology. The PTD's claims leverage known materials science techniques and design principles to enhance the original hemostatic composition concept. The modifications represent incremental improvements using standard engineering approaches within the established technological framework of the source patent.

Obvious Combinations & Variations

Source Patent Element
Anion exchanger with positively-charged groups bound to a matrix
PTD Variation
Nanofibrous matrix incorporating the anion exchanger with self-assembling hierarchical structures
Obviousness Reasoning
A PHOSITA would find it obvious to modify matrix structures using known nanomaterials fabrication techniques, as matrix design represents a predictable design choice in materials engineering
Source Patent Element
Hemostatic composition comprising anion exchanger and calcium salt
PTD Variation
Personalized hemostatic composition tailored to individual bleeding profiles
Obviousness Reasoning
Customizing medical compositions based on patient-specific characteristics is a known approach in personalized medicine, representing an obvious extension of standard medical design principles
Source Patent Element
Hemostatic composition in slurry or liquid form
PTD Variation
Wearable device incorporating hemostatic composition with integrated bleeding detection sensors
Obviousness Reasoning
Integrating medical compositions with sensor technologies is a predictable technological evolution, utilizing known medical device design strategies
Source Patent Element
Composition devoid of blood clotting cascade proteins
PTD Variation
Hemostatic composition with conjugated targeting moieties for selective bleeding site interaction
Obviousness Reasoning
Developing targeted drug delivery mechanisms represents a standard approach in biomedical engineering, using known chemical conjugation techniques
Source Patent Element
Calcium salt-containing hemostatic composition
PTD Variation
Method of enhancing hemostatic efficacy through low-level electrical current application
Obviousness Reasoning
Exploring alternative activation mechanisms for medical compositions is a routine investigative approach in biomedical research, representing an obvious experimental variation
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the published technical disclosure would have been obvious to a person having ordinary skill in the art at the time of invention, with a reasonable expectation of success, when considered in light of US Patent 11857564. The incremental modifications represent predictable technological extensions employing standard engineering design principles within the established hemostatic composition technological domain.

Original Patent Information

Patent NumberUS 11,857,564
TitleHemostatic composition comprising an anion exchanger and a calcium salt
Assignee(s)Omrix Biopharmaceuticals Ltd.